John Garner

mPEG-PLA from PolySciTech used in the development of a Vessel-Perfusion system to better track nanoparticle motility and uptake

Blog Post created by John Garner on Dec 23, 2019

A classic problem with medicine is that the administered dose has poor uptake or targeting which reduces the efficacy of the drug. Having a better understanding for how drug loaded in nanoparticles move and are uptaken in blood vessels will enable the development of improved targeted therapies. Recently, researchers at Yale University used mPEG-PLA (Polyvivo AK054) from PolySciTech (www.polyscitech.com) as part of evaluating their developed perfusion testing chamber. This research holds promise to lead to improved nanotherapeutics in the future. Read more: Lysyy, Taras, Laura G. Bracaglia, Lingfeng Qin, Claire Albert, Jordan S. Pober, George Tellides, W. Mark Saltzman, and Gregory T. Tietjen. "Ex vivo isolated human vessel perfusion system for the design and assessment of nanomedicines targeted to the endothelium." Bioengineering & Translational Medicine. https://aiche.onlinelibrary.wiley.com/doi/abs/10.1002/btm2.10154

 

“Abstract: Endothelial cells play a central role in the process of inflammation. Their biologic relevance, as well as their accessibility to IV injected therapeutics, make them a strong candidate for treatment with molecularly‐targeted nanomedicines. Typically, the properties of targeted nanomedicines are first optimized in vitro in cell culture and then in vivo in rodent models. While cultured cells are readily available for study, results obtained from isolated cells can lack relevance to more complex in vivo environments. On the other hand, the quantitative assays needed to determine the impact of NP design on targeting efficacy are difficult to perform in animal models. Moreover, results from animal models often translate poorly to human systems. To address the need for an improved testing platform, we developed an Isolated Vessel Perfusion System (IVPS) to enable dynamic and quantitative study of vascular‐targeted nanomedicines in readily obtainable human vessels isolated from umbilical cords or placenta. We show that this platform technology enables the evaluation of parameters that are critical to targeting efficacy (including flow rate, selection of targeting molecule, and temperature). Furthermore, biologic replicates can be easily produced by evaluating multiple vessel segments from the same human donor in independent, modular chambers. The chambers can also be adapted to house vessels of a variety of sizes, enabling subsequent study of vessel segments in vivo following transplantation into immunodeficient mice. We believe this perfusion system can help to address long‐standing issues in endothelial targeted nanomedicines and thereby enable more effective clinical translation.”

 

- Save-the-date: Akina, Inc's third annual Biotech-Pharma-Cancer-Research (BPCR) conference is August 26 at Kurz Purdue Technology Center (KPTC) (http://bpcrconference.com/). 

 

- Notice: Akina, Inc. will be closed December 24th through January 1st for the holidays. Orders placed during this time will be processed when we re-open on Thursday, January 2, 2020

Outcomes